Thalidomide and lenalidomide for the treatment of refractory dermatologic conditions
- 1 July 2016
- journal article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 75 (1) , 210-212
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Review of thalidomide use in the pediatric populationJournal of the American Academy of Dermatology, 2015
- Lenalidomide in treatment-refractory cutaneous lupus erythematosus: Efficacy and safety in a 52-week trialJournal of the American Academy of Dermatology, 2014
- Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myelomaBlood, 2009
- Thalidomide for the treatment of resistant cutaneous lupus: Efficacy and safety of different therapeutic regimensThe American Journal of Medicine, 2005
- Rediscovering thalidomide: A review of its mechanism of action, side effects, and potential usesJournal of the American Academy of Dermatology, 1996